Thar Pharmaceuticals (THAR) Acquired

Developing novel oral therapies for chronic pain utilizing the 505(b)(2) pathway.

Health Care - Biotechnology

IPO Performance
Latest Trade ()
First Day Return
Return from IPO
 
Thar Pharmaceuticals IPO News more
  • .
IPO Data
IPO File Date 08/19/2016
Offer Price
Price Range n/a
Offer Shares (mm) n/a
Deal Size ($mm) $50
 
IPO Data
IPO Date
Offer Price
Price Range n/a
Offer Shares (mm) n/a
Deal Size ($mm) $$50
 
Underwriters
more
Business Overview
Developing novel oral therapies for chronic pain utilizing the 505(b)(2) pathway.
Developing novel oral therapies for chronic pain utilizing the 505(b)(2) pathway.
more
Company Data
Headquarters Pittsburgh, PA
Founded 2006
Employees 4
Website www.tharpharma.com
 

Performance vs. IPO Index (IPOUSA)